PASSAGE BIO, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PASSAGE BIO, INC. stock issued during period, value, new issues for the quarter ending 2024-12-31 was $0.00.
- PASSAGE BIO, INC. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $0.00.
- PASSAGE BIO, INC. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $0.00.
- PASSAGE BIO, INC. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $8.74M.
- PASSAGE BIO, INC. stock issued during period, value, new issues for fiscal 2021 was $165.81M, a 27.12% decline from fiscal 2020.
- PASSAGE BIO, INC. stock issued during period, value, new issues for fiscal 2020 was $227.50M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $0.00 derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $8.74M S-4/A · filed 2026-09-03 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | |
| 2024-03-31 | $8.74M 10-Q · filed 2025-05-13 | |
| 2021-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $165.81M 10-K · filed 2023-03-06 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $165.81M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $165.81M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $165.81M 10-Q · filed 2022-05-16 | $165.81M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $227.50M 10-K · filed 2022-03-03 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | |
| 2020-03-31 | $227.50M 10-Q · filed 2021-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |